Noble Life Sciences Acquires Spring Valley Laboratories
Complete the form below to unlock access to ALL audio articles.
Noble Life Sciences has announced the acquisition of Spring Valley Laboratories (Sykesville, MD), a full service, GLP (Good Laboratory Practice)-compliant, preclinical contract research organization (CRO) for the development of drugs, vaccines, and medical devices.
The acquisition greatly expands Noble’s services to include GLP regulatory standards, studies in small and large animals, and testing capabilities for vaccines and medical devices.
Combined with Noble’s recognized strength conducting studies directed at early-stage products, the acquisition of Spring Valley Laboratories extends the Company’s suite of offerings across the full continuum of preclinical studies from initial product discovery through regulation-compliant studies for submission to FDA and other similar agencies.
Founded in 1980, Spring Valley Laboratories has extensive experience in vaccine and drug toxicity, medical devices, GLP in vivo product release tests, derivation and maintenance of animal breeding colonies, production of custom antibodies, and development of animal models. The company provides all aspects of the process from design to regulatory support of IND, IDE, or PMA submissions.
Alain Cappeluti, President of Noble Life Sciences, said, “Spring Valley Laboratories’ GLP and large animal testing capabilities will be an excellent fit with our small animal testing capabilities and in vitro drug discovery expertise. This will enable us to engage with our clients throughout the preclinical development process."
Spring Valley Laboratories’ facilities consist of 24,000 square feet of animal housing, support, and laboratory space securely situated on a twenty-five acre campus including 8,000 sq. ft. of conventional and 14,000 sq. ft. of specific pathogen free (SPF) housing and support space for both small and large animals. Support spaces include two surgical suites with recovery room, intensive care area, and preparation area as well as laboratories for clinical pathology, designated test article storage and preparation, specimen analysis, necropsy and secure access-controlled archives.
Amy Dyke, President and CEO of Spring Valley Laboratories, commented, "I'm thrilled with the acquisition by Noble Life Sciences. Our GLP-compliant safety and efficacy testing services will expand Noble’s early stage research services. This definitely enhances our combined offerings for clients developing drugs, vaccines, and medical devices.”
Spring Valley Laboratories will become a division of Noble Life Sciences; Mr. Cappeluti will serve as President of the division. No staff changes at Spring Valley Laboratories are currently contemplated; Ms. Dyke and Robyn Shaw, the previous owners, will continue to provide their operational expertise.
